At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
LY3009385 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Ascending Dose (SAD) Study of LY3009385 in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating LY3009385 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented. This study is approximately 28 days not including screening. Screening is required within 28 days prior to the start of the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedNov 22, 2011
Enrollment StartNov 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.6 years ago
Interventions
LY3009385drug
Placebodrug